Aizon entered a partnership with Spanish firm, aggity to help boost the effectiveness of biopharmaceutical firms drug manufacturing systems.
“We are excited to partner with Aizon, a joint effort to bring market-leading technology that is purpose-built for the industry to our customers, for real and impactful improvements on how to create value from manufacturing data in GxP environments,” aggity CEO and President Óscar Pierre said in a press release issued by Aizon.
The press release stated the enterprise AI software provider will work with the Barcelona and Madrid-based company, known to specialize in business digital innovative solutions. Together, the companies will work to digitally transform pharmaceutical and biotech operations.
“We are delighted to join forces so that pharma and biotech companies in the region can increase operational efficiencies from development through manufacturing, improve processes, and accelerate the delivery of therapeutic products,” SVP of Global Sales & Alliances for Aizon, Glenn Griffin, said.
The partnership will also target the monitorization of aggity’s customer-base, identifying and solving operational issues, and improving the system’s overall performance, the release stated.
The tweaks the companies plan to integrate are based on Aizon’s Saas platform, and will utilize Industry 4.0 technologies like artificial intelligence and machine learning, among other technologies.
Members representing both firms will collaborate to integrate aggity’s digital transformation tactics with Aizon’s data and technological knowledge.
“Aizon innovates how customers use data to achieve actionable insights within and across manufacturing sites,” Griffin said.